Development and evaluation of a health-promoting meal for late middle-aged women in menopause

Impact of a tailored meal plan on metabolic health in late middle-aged women: an 8-week pre-post intervention trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11827482

Enrollment

Registered

2025-10-16

Start date

2021-06-07

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Late middle-aged postmenopausal women Other

Interventions

Sixty-one participants underwent the intervention and were provided with a health-promoting meal plan for 8 weeks. The meal plan was developed by registered dietitians to enrich four major nutrients

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women aged >50 and <65 years 2. Subjects with a low intake level of at least one of the target nutrients, below the Korean dietary recommendations (75 mg isoflavones, 2.0 g omega-3 fatty acids, 18.8 g dietary fiber, and 600 mg calcium), as assessed by a 3-day dietary survey (2 weekdays and 1 weekend day)

Exclusion criteria

Exclusion criteria: 1. Subjects with hypersensitivity to specific foods or ingredients 2. Subjects with difficulty using smartphones

Design outcomes

Primary

Measure	Time frame
Blood metabolic health markers (glucose and lipid parameters) will be measured at baseline and 8 weeks using standard enzymatic and immunoturbidimetric assays.	—

Secondary

Measure	Time frame
1. Menopausal symptoms measured using the Kupperman Index and Pittsburgh Sleep Quality Index (PSQI) at baseline and 8 weeks 2. Hormone levels (estradiol [E2] and follicle-stimulating hormone [FSH]) measured using chemiluminescence microparticle immunoassay and electrochemiluminescence microparticle immunoassay at baseline and 8 weeks 3. Continuous glucose monitoring (CGM) measured using iPro2 (Medtronic Diabetes, Northridge, CA, USA) at baseline and 8 weeks 4. Plasma and urine metabolomics measured using GC-TOF-MS at baseline and 8 weeks 5. Nutritional intake measured using mobile application during 8 weeks intervention period	—

Measure

Time frame

1. Menopausal symptoms measured using the Kupperman Index and Pittsburgh Sleep Quality Index (PSQI) at baseline and 8 weeks 2. Hormone levels (estradiol [E2] and follicle-stimulating hormone [FSH]) measured using chemiluminescence microparticle immunoassay and electrochemiluminescence microparticle immunoassay at baseline and 8 weeks 3. Continuous glucose monitoring (CGM) measured using iPro2 (Medtronic Diabetes, Northridge, CA, USA) at baseline and 8 weeks 4. Plasma and urine metabolomics measured using GC-TOF-MS at baseline and 8 weeks 5. Nutritional intake measured using mobile application during 8 weeks intervention period

—

Countries

Korea, South

Contacts

Public ContactYoon Jung Park

park.yoonjung@ewha.ac.kr+82 2-3277-6533

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026